Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

Protein phosphatase 2a (PP2A) has an important role ... become the paradigm for therapy decision making in other types of cancer. Figure 2: BCR-ABL contributes to differentiation arrest through ...

LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive ...